Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocugen (OCGN) EBITDA (2016 - 2025)

Ocugen (OCGN) has disclosed EBITDA for 12 consecutive years, with -$17.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 27.77% year-over-year to -$17.7 million, compared with a TTM value of -$67.8 million through Dec 2025, down 25.56%, and an annual FY2025 reading of -$67.8 million, down 25.56% over the prior year.
  • EBITDA was -$17.7 million for Q4 2025 at Ocugen, up from -$20.0 million in the prior quarter.
  • Across five years, EBITDA topped out at -$7.1 million in Q1 2021 and bottomed at -$26.0 million in Q2 2021.
  • Average EBITDA over 5 years is -$16.2 million, with a median of -$15.3 million recorded in 2024.
  • The sharpest move saw EBITDA tumbled 618.1% in 2021, then surged 49.97% in 2023.
  • Year by year, EBITDA stood at -$14.6 million in 2021, then plummeted by 50.49% to -$21.9 million in 2022, then soared by 49.97% to -$11.0 million in 2023, then decreased by 26.22% to -$13.9 million in 2024, then dropped by 27.77% to -$17.7 million in 2025.
  • Business Quant data shows EBITDA for OCGN at -$17.7 million in Q4 2025, -$20.0 million in Q3 2025, and -$14.8 million in Q2 2025.